 Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pivotal Phase 3 clinical studies evaluating sofpironium bromide gel, 15 as a potential treatment for primary axillary hyperhidrosis - - - On track to initiate the Cardigan II study, the second U.S. pivotal Phase 3 clinical study, later this year - - - Planned commercial launch of ECCLOCK in Japan by development partner, Kaken, expected by the end of 2020, which follows regulatory approval received in the third quarter 